BeiGene Ltd. (NASDAQ:BGNE) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Monday.
According to Zacks, “BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company’s clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands. “
Other research analysts have also issued research reports about the stock. Maxim Group set a $41.00 price objective on shares of BeiGene and gave the stock a “buy” rating in a research note on Saturday, October 8th. Cowen and Company reissued a “buy” rating on shares of BeiGene in a research note on Friday, October 7th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $40.00.
Shares of BeiGene (NASDAQ:BGNE) opened at 31.47 on Monday. BeiGene has a 52-week low of $22.51 and a 52-week high of $37.89. The firm has a 50-day moving average of $0.00 and a 200 day moving average of $0.00.
BeiGene (NASDAQ:BGNE) last issued its earnings results on Thursday, November 10th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by $0.30. On average, analysts anticipate that BeiGene will post ($3.96) EPS for the current fiscal year.
In other news, Director Donald W. Glazer sold 47,149 shares of BeiGene stock in a transaction that occurred on Tuesday, September 27th. The shares were sold at an average price of $29.61, for a total value of $1,396,081.89. Following the sale, the director now directly owns 4,881,997 shares in the company, valued at $144,555,931.17. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Donald W. Glazer sold 67,252 shares of BeiGene stock in a transaction that occurred on Wednesday, September 21st. The shares were sold at an average price of $31.42, for a total transaction of $2,113,057.84. Following the completion of the sale, the director now owns 4,882,000 shares in the company, valued at $153,392,440. The disclosure for this sale can be found here.
Several hedge funds have recently bought and sold shares of BGNE. BlackRock Inc. increased its stake in BeiGene by 3,410.1% in the second quarter. BlackRock Inc. now owns 3,826 shares of the company’s stock worth $114,000 after buying an additional 3,717 shares during the period. BlackRock Institutional Trust Company N.A. increased its stake in BeiGene by 67.9% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 6,404 shares of the company’s stock worth $191,000 after buying an additional 2,589 shares during the period. Bank of Montreal Can acquired a new stake in BeiGene during the second quarter worth about $191,000. Credit Suisse AG increased its stake in BeiGene by 9.1% in the third quarter. Credit Suisse AG now owns 12,000 shares of the company’s stock worth $370,000 after buying an additional 1,000 shares during the period. Finally, Susquehanna International Group LLP acquired a new stake in BeiGene during the third quarter worth about $455,000. Institutional investors own 25.83% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was first posted by Mideast Time and is owned by of Mideast Time. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this report can be accessed at http://www.mideasttime.com/zacks-investment-research-upgrades-beigene-ltd-bgne-to-hold/1417787.html. <span
BeiGene Company Profile
BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BeiGene Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.